Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study

Phase 2

• Conditions: Patients with non-squamous non-small cell lung cancer previously untreated

• Registration Number: JPRN-UMIN000014345
• Lead Sponsor: Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-06-23
• Study Completion: 2017-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

(1)Received transfusion or G-CSF within 14 days prior to enrollment (2)Urine protein>=2+ (3)History of drug allergy (4)Active multiple cancers (5)Severe infection (6)High fever (7)Abnormal cardiac function (8)Severe pulmonary disease; Interstitial pneumonia, severe COPD, pulmonary thromboembolism (9)History of hematoemesis, ileus and gastroduodenal ulcer (10)Need for drainage of pleural effusion, acsites or pericardial effusion (11)Medically uncontrolled thromboembolism (12)Symptomatic CNS metastases previously untreated (13)CNS or Psychological disorders (14)Medically uncontrolled hypertension or diabetes mellitus (15)Nonhealing wound and surgery within 4 weeks before treatment (16)History of hemoptysis; one-half teaspoon of bright red blood per event (17)Recent use of aspirin (>=325 mg/day) (18)Severe bone marrow suppression (19)Pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified